GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01787097).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top